Bicara Therapeutics Inc. Common Stock (BCAX NASDAQ) stock market data APIs
$10.2001
-0.62(-6.1%)
as of July 14, 2025
Try our APIs with
free plan!
Bicara Therapeutics Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Prev. Close
10.2001
Open
9.5769
High
10.6017
Low
9.5769
52 wk Range
7.8-28.09
Market Cap
901 M
Shares Outstanding
54 386 K
EPS
-0.68
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bicara Therapeutics Inc. Common Stock data using free add-ons & libraries
Get Bicara Therapeutics Inc. Common Stock Fundamental Data
Bicara Therapeutics Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -58 299 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: NaN
Get Bicara Therapeutics Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bicara Therapeutics Inc. Common Stock News
New
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III
Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May ...
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-...
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ...
Bicara Therapeutics Reports Promising Phase 1/1b Trial Results for Ficerafusp Alfa in HPV-Negative Head and Neck Cancer
Bicara Therapeutics reports encouraging Phase 1/1b results for ficerafusp alfa in HPV-negative head and neck cancer patients. Quiver AI Summary Bicara Therapeutics Inc. has announced promising data ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
